Figure 3. Provider Reported Utility of Pharmacogenomic Information to Guide Prescribing.
At visits where pharmacogenomic information influenced prescribing (as determined by independent assessment12, n=57 clinic visits), providers most frequently stated, on the provider experience survey, that pharmacogenomic information helped them to make a more informed therapeutic decision (cited for 86.0% of instances where a pharmacogenomic result guided prescribing), yet they simultaneously also reported that the given pharmacogenomic results increased the likelihood that their patient would respond favorably to treatment (68.2% of instances), helped choose a therapy from multiple options (50.0%), reduced the likelihood that their patient will experience an adverse reaction (27.3%), reinforced an originally intended prescribing decision (22.7%), and helped select a specific dose (15.9%). Providers could choose more than one response for each visit. Bars represent the number of times the response was chosen as a percentage of the total number of surveys on which the question was answered.
*Out of 761 total experience surveys sent for visits at which pharmacogenomic results were accessed, 395 (51.9%) were returned. Seventeen of the 18 study providers returned ≥1 experience survey (median surveys returned/provider: 15, range 0–77).